These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30810619)

  • 1. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration.
    Nunes RP; Hirai FE; Barroso LF; Badaró E; Novais E; Rodrigues EB; Maia M; Magalhães O; Farah ME
    Arq Bras Oftalmol; 2019; 82(3):225-232. PubMed ID: 30810619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
    Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.
    Davis J; Olsen TW; Stewart M; Sternberg P
    Am J Ophthalmol; 2011 Oct; 152(4):509-14. PubMed ID: 21961847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks.
    Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma S; Missotten T
    Acta Ophthalmol; 2019 Feb; 97(1):107-112. PubMed ID: 30369062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
    Ehlers JP; Spirn MJ; Shah CP; Fenton GL; Baker PS; Regillo CD; Ho AC
    Ophthalmic Surg Lasers Imaging; 2010; 41(2):182-9. PubMed ID: 20307035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.
    Krebs I; Schmetterer L; Boltz A; Told R; Vécsei-Marlovits V; Egger S; Schönherr U; Haas A; Ansari-Shahrezaei S; Binder S;
    Br J Ophthalmol; 2013 Mar; 97(3):266-71. PubMed ID: 23292928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
    Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture.
    Rosenfeld PJ
    Am J Ophthalmol; 2019 Aug; 204():26-45. PubMed ID: 30851267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results.
    Nishimura T; Machida S
    Jpn J Ophthalmol; 2019 Jan; 63(1):90-99. PubMed ID: 30470956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Westborg I; Albrecht S; Rosso A
    Retina; 2017 Nov; 37(11):2035-2046. PubMed ID: 28141748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
    Son BK; Kwak HW; Kim ES; Yu SY
    Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.
    Enseleit F; Michels S; Sudano I; Stahel M; Zweifel S; Schlager O; Becker M; Winnik S; Nägele M; Flammer AJ; Neidhart M; Graf N; Matter CM; Seifert B; Lüscher TF; Ruschitzka F
    Ophthalmologica; 2017; 238(4):205-216. PubMed ID: 28866675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAIN HEALTH ASSESSMENT IN MACULAR DEGENERATION PATIENTS UNDERGOING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS (THE BHAM STUDY): An Interim Analysis.
    Ray SK; Manz SN
    Retina; 2021 Aug; 41(8):1748-1753. PubMed ID: 33346625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.